CA-XSOLLA
5.3.2024 14:01:29 CET | Business Wire | Press release
Xsolla, a global video game commerce company, has introduced Cross-Play and Cross-Pay, an innovative approach to mobile game monetization. In response to the evolving landscape, Xsolla’s suite of solutions enables mobile game developers to seamlessly transition their games from mobile to the web, desktop, and cloud while offering diverse monetization models out-of-the-box to power profitable direct-to-consumer sales for game developers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305100421/en/
(Graphic: Xsolla)
As the video game industry evolves, players anticipate engaging with their favorite titles seamlessly across all platforms, form factors, and control methods. This growing expectation places Cross-Play at the forefront of modern game development strategies. Mobile game developers can now effortlessly deploy their games across Mobile, PC, Console, Cloud, and Web with Xsolla Launcher and Xsolla Cloud Gaming.
Xsolla Launcher makes it easier for developers to leverage the capabilities of desktop computing, including enhanced graphics, gameplay depth, and longer play sessions when porting mobile games to PC.
Cloud Gaming for Mobile Games, in turn, is a strategic extension of the core Xsolla Cloud Gaming solution. It enables mobile video game developers to expand cross-platform by deploying game builds to cloud platforms directly from the developer's own branded landing page, allowing them to deliver flexible monetization mechanics for mobile users.
Cross-Play experience ensures consistent and fair monetization strategy across all platforms for developers around the world. This approach ensures equal access to game content for players, thereby enhancing the overall playing experience while adhering to platform rules and guidelines. Xsolla Web Shop, a leading solution for web purchases, is a foundation for the Direct-to-Consumer strategy for mobile game developers.
Web Shops are easily customizable branded online stores fully equipped to facilitate in-game web purchases. The next iteration of the Xsolla Web Shop Solution includes innovative updates drawing on Xsolla's expertise gained from launching over 210 Web Shops and 40 of the top 100 highest-grossing mobile games worldwide. Xsolla Web Shop introduces advanced LiveOps tools, additional personalization and engagement features, and an improved user flow for seamless purchases. Alongside these enhancements, Xsolla's experts are always available to offer guidance and support by providing best practices consultation in navigating the operation and management of web shops.
“The advancements made with Cross-Play Cross-Pay have been a focus of our innovation over the past year after collaborating with numerous partners and launching over 200 web shops in 2023. This extensive real-world application with customer feedback has helped mobile game developers to efficiently market their games online by operating within the platform guidelines,” said David Stelzer, President of Xsolla. “Cross-Play Cross-Pay is our strategic innovation to meet the continuously evolving demands of the ever-changing mobile game industry. By delivering a multi-platform solution for mobile game developers, we can help them to reach more players and to grow their business.”
This comprehensive suite of Cross-Play Cross-Pay solutions empowers mobile developers to ensure their games reach the widest possible audience by establishing deep and lasting connections with players around the globe.
For more information about Xsolla Web Shop 2.0 and its features, please visit: xsolla.pro/web-shop2
For more information about Xsolla Cloud Gaming for mobile and its features, please visit: xsolla.pro/cloud-gaming
For more information about Xsolla Launcher, please visit: xsolla.pro/xsolla-launcher
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305100421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom